Many therapies fail to meet real-world expectations because they are designed for the lab, not life. Innovations focus on clinical efficacy, which drives only 20% of health outcomes, while ignoring the 80% driven by crucial psychological, social, and environmental factors.

AI's most significant impact won't be on broad population health management, but as a diagnostic and decision-support assistant for physicians. By analyzing an individual patient's risks and co-morbidities, AI can empower doctors to make better, earlier diagnoses, addressing the core problem of physicians lacking time for deep patient analysis.

In its Phase 2 trial, Acadia isn't using biomarkers to discover new insights but to confirm patients have the biological underpinnings of Alzheimer's disease. This marks a significant shift, demonstrating that biomarkers have matured into a standard diagnostic component for ensuring a homogenous and accurately defined patient population in clinical research.

The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

To overcome resistance, AI in healthcare must be positioned as a tool that enhances, not replaces, the physician. The system provides a data-driven playbook of treatment options, but the final, nuanced decision rightfully remains with the doctor, fostering trust and adoption.

Successful MedTech innovation starts by identifying a pressing, real-world clinical problem and then developing a solution. This 'problem-first' approach is more effective than creating a technology and searching for an application, a common pitfall for founders with academic backgrounds.

With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.

Biomarkers provide value beyond predicting patient response. Their core function is to answer 'why' a treatment succeeded or failed. This explanatory power informs sequential therapy decisions and provides crucial scientific insights that advance the entire medical field, not just the individual patient's case.

Gene therapy companies, which are inherently technology-heavy, risk becoming too focused on their platform. The ultimate stakeholder is the patient, who is indifferent to whether a cure comes from gene editing, a small molecule, or an antibody. The key is solving the disease, not forcing a specific technological solution onto every problem.